CYP2D6 and metabolic dysfunction-associated steatotic liver disease: An experimental study utilizing the CYP2D6 mouse model, which replicates several characteristic features of human AIH, such as interface hepatitis, hepatic fibrosis, and the formation of AIH-specific autoantibodies and CYP2D6-specific T cells, revealed that MASLD exacerbates AIH.